Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 7/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17318005 | 0.75 | NUDT1 (0.46) | CDK2PIK3CGCYP11B1ELANE | |
| SCHEMBL23942101 | 0.74 | PIK3CG (0.36) | CDK2PIK3CGELANE | |
| SCHEMBL5496407 | 0.69 | NUDT1 (0.56) | CDK2PIK3CGELANESMPD3AXL | |
| SCHEMBL10677361 | 0.69 | ELANE (0.35) | CYP11B1ELANE | |
| SCHEMBL5047316 | 0.66 | GABRA1 (0.35) | — | |
| SCHEMBL21937448 | 0.65 | PIK3CG (0.45) | PIK3CGSMPD3AXL | |
| SCHEMBL23744915 | 0.65 | PIK3CG (0.32) | PIK3CGSMPD3AXL | |
| SCHEMBL19677948 | 0.65 | KDM4E (0.33) | PIK3CGKDM4DSMPD3AXL | |
| SCHEMBL13377380 | 0.64 | KDM4E (0.33) | PIK3CGSMPD3AXL | |
| SCHEMBL22835753 | 0.64 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514443-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080051421-A1 | Pyrazolo-pyridine | WICHMANN JUERGEN | 2008-02-28 | — | — | US | disclosed |
| US-7329662-B2 | Pyrazolo-pyridine | HOFFMANN-LA ROCHE INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | CDK2 306/4885PIK3CG 3362/4885CYP11B1 107/4885 |
| US-20080051421-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | CDK2 306/4885PIK3CG 3362/4885CYP11B1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.